Method to elicit an antitumor response with human prostate-specific antigen

• US 5,925,362 A
• Filed: 08/10/1994
• Issued: 07/20/1999
• Est. Priority Date: 08/11/1993
• Status: Expired due to Fees

• Current Assignee: Jenner Technologies Co.
• Original Assignee: Jenner Technologies Co.
• Inventors: Maida, Anthony E. III, Spitler, Lynn E.
• Primary Examiner(s): Chan, Christina Y.
• Assistant Examiner(s): Gambel, Phillip
• Application Number:
  US08/288,057
• Time in Patent Office: 1,805 Days
• Field of Search: 424/130.1, 424/131.1, 424/138.1, 424/141.1, 424/152.1, 424/184.1, 424/193.1, 424/277.1, 424/520, 424/93.2, 435/320.1, 530/350, 530/387.2
• US Class Current: 424/277.1
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/0011 Cancer antigens
• CPC Class Codes: A61P 13/08 of the prostate
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C07K 16/4241 against anti-human or anti-animal Ig
• CPC Class Codes: Y10S 424/812 Liposome comprising an antibody, antibody fragment, antigen, or other specific or nonspecific immunoeffector

Abstract

Vaccines capable of eliciting an immune antitumor response for prostate tumors are disclosed. The active ingredient in such vaccines is selected from the group consisting of human PSA and expression system capable of generating in situ human PSA.

Claims

1. A method to elicit an antitumor immune response to prostate tumors in a subject which comprises administering to said subject at least one active ingredient formulated for administration to said subject, wherein said active ingredient elicits an immune response to human prostate-specific antigen (PSA) and wherein said active ingredient is selected from the group consisting of

human PSA;

and

an expression system capable of generating in situ said human PSA.

2. The method of claim 1 wherein said active ingredient is human PSA.

3. The method of claim 1 wherein said expression system comprises DNA comprising a nucleotide sequence encoding said human PSA.

4. The method of claim 3 wherein said expression system is on expression vector for said human PSA.

5. The method of claim 1 wherein said active ingredient is formulated to be encapsulated in a liposome or coupled to a liposome and

wherein said liposomes optionally contain an adjuvant or are precipitated with alum.

6. The method of claim 1 which further includes at least one adjuvant capable of enhancing said antitumor immune response.

7. The method of claim 6 wherein said adjuvant is selected from the group consisting of Freund'"'"'s complete adjuvant;

alum;

lipid A;

monophosphoryl lipid A;

Bacillus Calmette-Guerin (BCG) or other bacteria polysaccharides;

saponins;

detoxified endotoxin (DETOX);

muramyl tripeptide or muramyl dipeptide or their derivatives;

SAF1;

lymphokines;

cytokines;

colony stimulating factors;

nonionic block copolymers; and

immune stimulating complexes (ISCOMS).

8. The method of claim 1 wherein said subject is afflicted with metastatic prostate cancer;

and/or wherein said subject has been surgically treated to excise said tumor but is at risk for recurrence.